Insight, China's Pharmaceutical Industry

Gilead Foundation Commits $12 Million to Community Health Worker HIV Prevention Initiative – 33 Organizations Across 15 U.S. Jurisdictions

The Gilead Foundation announced a USD 12 million investment in 33 community‑based organizations spanning 14 states and...

Company Drug

Eli Lilly’s Eloralintide Wins CDE Approval for Phase III Trials in China – Weekly Amylin Agonist Targets Weight Management Market

Fineline Cube Mar 5, 2026

Eli Lilly and Company (NYSE: LLY) announced that China’s Center for Drug Evaluation (CDE) under...

Company Drug

Pyrotech Therapeutics’ PTT-936 Wins NMPA Approval – Novel ALPK1 Agonist Targets Bladder Cancer

Fineline Cube Mar 5, 2026

Pyrotech (Beijing) Biotechnology Co., Ltd. (“Pyrotech Therapeutics”) announced that its internally developed small‑molecule innate immune...

Company Drug

Konruns Pharma’s KC1036 Wins NMPA Approval – Dual‑Target VEGFR2/AXL Inhibitor Enters IO Combination Trials

Fineline Cube Mar 5, 2026

Beijing Konruns Pharmaceutical Co., Ltd (SHA: 603590) announced that China’s National Medical Products Administration (NMPA) has...

Company Deals

Rallybio to Acquire Candid Therapeutics in $700M+ Merger – Creates Leading Autoimmune T‑Cell Engager Company

Fineline Cube Mar 5, 2026

Rallybio Corporation (NASDAQ: RLYB) and Candid Therapeutics, Inc. announced a definitive merger agreement whereby Rallybio will...

Company Drug

Sichuan Biokin’s CD33 ADC BL-M11D1 Wins NMPA Approval – Expands into Myelodysplastic Syndromes

Fineline Cube Mar 5, 2026

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) announced that China’s National Medical Products Administration (NMPA) has...

Company Drug

CMS’s CMS-D008 Wins NMPA Approval – INHBE siRNA Targets Fat‑Selective Weight Loss

Fineline Cube Mar 5, 2026

China Medical System Holdings Limited (CMS, HKG: 0867) announced clinical study approval from China’s National Medical...

Medical Device

Sanyou Medical’s 3D‑Printed SWINGO-3D Lumbar Cage Wins FDA 510(K) – Advances Spinal Fusion Technology

Fineline Cube Mar 5, 2026

Sanyou Medical (SHA: 688085) announced that its French subsidiary Implanet has received FDA 510(K) clearance for...

Company Deals

Edding Genor Expands ANGPTL3 siRNA Rights to Global – Restructures Napeptide Partnership

Fineline Cube Mar 4, 2026

Edding Genor Group Holdings Limited (HKG: 6998) announced a supplemental agreement and termination agreement with Napeptide...

Company Drug

Sihuan Pharma’s Bireociclib Wins NMPA Approval for First‑Line HR+/HER2‑ Breast Cancer – CDK2/4/6 Inhibitor Expands Label

Fineline Cube Mar 4, 2026

Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced that Xuanyuening (bireociclib), a Category 1 CDK2/4/6 inhibitor developed...

Company Deals

Aidea Pharma Raises RMB 1.28B – $111M Allocated to Global HIV Integrase Inhibitor Development

Fineline Cube Mar 4, 2026

Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) announced the completion of a financing round raising RMB 1.277 billion...

Company Drug

Bio-Thera’s Stelara Biosimilar Usymro Wins UK Approval – Expands European Market Access via Gedeon Richter

Fineline Cube Mar 4, 2026

Bio-Thera Solutions Ltd (SHA: 688177) announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA)...

Company Deals

Star Sports Medicine Files Hong Kong IPO – Sports Medical Device Maker Targets Soft Tissue Injury Market

Fineline Cube Mar 4, 2026

Star Sports Medicine Co., Ltd., a China‑based sports medical device manufacturer, submitted a prospectus to...

Company Drug

Kexing Biopharma’s GB19 Wins NMPA Approval for Cutaneous Lupus – BDCA2‑Targeted Therapy Expands Autoimmune Pipeline

Fineline Cube Mar 4, 2026

Kexing Biopharm Co., Ltd. (SHA: 688136) announced clinical trial approval from China’s National Medical Products Administration...

Company Drug

J&J’s Nipocalimab Wins FDA Fast Track for Lupus – FcRn Blocker Targets Autoantibody Diseases

Fineline Cube Mar 4, 2026

Johnson & Johnson (J&J, NYSE: JNJ) announced that its investigational drug nipocalimab has received Fast Track...

Company Deals

Leman Biotech Raises RMB 200M Series A+ – Advances Ultra‑Low‑Dose Metabolically Armored CAR‑T

Fineline Cube Mar 4, 2026

Leman Biotech Co., Ltd. announced the completion of a Series A+ financing round totaling nearly...

Company Digital

Insilico Medicine Launches AI‑Powered Automated Partnering System – Transforms Biotech Business Development

Fineline Cube Mar 4, 2026

Insilico Medicine (HKG: 3696), a generative AI‑driven biotech, announced the pilot launch of its Automated Partnering...

Company Deals

Teva Secures $400M Blackstone Funding for Duvakitug – TL1A Antibody Advances in IBD Phase III

Fineline Cube Mar 4, 2026

Teva Pharmaceuticals (NYSE: TEVA) and Blackstone Life Sciences (BXLS) announced a $400 million strategic funding agreement over...

Company Drug Medical Device

Asieris Pharma’s Cevira Wins NMPA Approval – World’s First Non‑Surgical Photodynamic Therapy for Cervical Lesions

Fineline Cube Mar 4, 2026

Jiangsu Asieris Pharmaceuticals Co., Ltd. (SHA: 688176), a urogenital cancer specialist, announced marketing approval from China’s...

Company Deals Drug

Antengene Licenses ATG-201 to UCB in $1.1B+ Deal – CD19/CD3 T‑Cell Engager Targets Autoimmune Diseases

Fineline Cube Mar 4, 2026

Antengene Corp., Ltd (HKG: 6996) announced a licensing agreement with UCB (EBR: UCB), granting the Belgium‑based biopharma...

Insight, China's Pharmaceutical Industry

Eli Lilly in Advanced Talks to Acquire Kelonia Therapeutics for Over $2 Billion – Strengthening CAR-T Cell Therapy Portfolio

AbbVie Partners with Santen China for Exclusive Distribution of Five Glaucoma Franchise Products

Annoroad Gene Technology Files for Hong Kong IPO to Capitalize on Integrated Molecular Diagnostics Platform

Mabwell Bioscience Expands Southeast Asia Reach with Malaysian Licensing Deal for Denosumab Biosimilars Rexeva and Denosu

Tigermed and Alibaba Cloud Forge Alliance to Build AI-Powered Ecosystem for Intelligent Clinical Trials

Xuanzhu Biopharmaceutical Reports Landmark Phase III DIAMOND-2 Results for Xuanfeining (Dirozalkib) in ALK-Positive NSCLC – 31.3-Month PFS Doubles Crizotinib Standard at AACR 2026

Sino Biopharmaceutical Reports 55% Response Rate for PD-1/VEGF Bispecific LM-299/MK-2010 in NSCLC at AACR 2026

Gilead Foundation Commits $12 Million to Community Health Worker HIV Prevention Initiative – 33 Organizations Across 15 U.S. Jurisdictions

Eli Lilly’s Eloralintide Wins CDE Approval for Phase III Trials in China – Weekly Amylin Agonist Targets Weight Management Market

Pyrotech Therapeutics’ PTT-936 Wins NMPA Approval – Novel ALPK1 Agonist Targets Bladder Cancer

Konruns Pharma’s KC1036 Wins NMPA Approval – Dual‑Target VEGFR2/AXL Inhibitor Enters IO Combination Trials

Rallybio to Acquire Candid Therapeutics in $700M+ Merger – Creates Leading Autoimmune T‑Cell Engager Company

Sichuan Biokin’s CD33 ADC BL-M11D1 Wins NMPA Approval – Expands into Myelodysplastic Syndromes

CMS’s CMS-D008 Wins NMPA Approval – INHBE siRNA Targets Fat‑Selective Weight Loss

Sanyou Medical’s 3D‑Printed SWINGO-3D Lumbar Cage Wins FDA 510(K) – Advances Spinal Fusion Technology

Edding Genor Expands ANGPTL3 siRNA Rights to Global – Restructures Napeptide Partnership

Sihuan Pharma’s Bireociclib Wins NMPA Approval for First‑Line HR+/HER2‑ Breast Cancer – CDK2/4/6 Inhibitor Expands Label

Aidea Pharma Raises RMB 1.28B – $111M Allocated to Global HIV Integrase Inhibitor Development

Bio-Thera’s Stelara Biosimilar Usymro Wins UK Approval – Expands European Market Access via Gedeon Richter

Star Sports Medicine Files Hong Kong IPO – Sports Medical Device Maker Targets Soft Tissue Injury Market

Kexing Biopharma’s GB19 Wins NMPA Approval for Cutaneous Lupus – BDCA2‑Targeted Therapy Expands Autoimmune Pipeline

J&J’s Nipocalimab Wins FDA Fast Track for Lupus – FcRn Blocker Targets Autoantibody Diseases

Leman Biotech Raises RMB 200M Series A+ – Advances Ultra‑Low‑Dose Metabolically Armored CAR‑T

Insilico Medicine Launches AI‑Powered Automated Partnering System – Transforms Biotech Business Development

Teva Secures $400M Blackstone Funding for Duvakitug – TL1A Antibody Advances in IBD Phase III

Asieris Pharma’s Cevira Wins NMPA Approval – World’s First Non‑Surgical Photodynamic Therapy for Cervical Lesions

Antengene Licenses ATG-201 to UCB in $1.1B+ Deal – CD19/CD3 T‑Cell Engager Targets Autoimmune Diseases

You Missed

China’s NMPA Proposes New Quality Management Standards for Drug Retail Chains – Mandating Unified Systems Across Headquarters, Distribution Centers, and Stores

Xuanzhu Biopharmaceutical Reports Landmark Phase III DIAMOND-2 Results for Xuanfeining (Dirozalkib) in ALK-Positive NSCLC – 31.3-Month PFS Doubles Crizotinib Standard at AACR 2026

Sino Biopharmaceutical Reports 55% Response Rate for PD-1/VEGF Bispecific LM-299/MK-2010 in NSCLC at AACR 2026

Eli Lilly in Advanced Talks to Acquire Kelonia Therapeutics for Over $2 Billion – Strengthening CAR-T Cell Therapy Portfolio